radiosensitizers to improve the therapeutic outcomes of radiotherapy in cancer patients. Our previous efforts to identify novel radiosensitizers, using high-throughput screening targeting p53 and Nrf2 revealed a promising N-phenylpyrimidin-2-amine (PPA) lead compound. In the present study, 17 derivatives of this lead compound were examined, and it was found that 4-(4-fluorophenyl)-N-(4-nitrophenyl)-6-phenylpyrimidin-2-amine
放射疗法是最常见的癌症治疗方法之一,但是放射抵抗和对正常组织的损伤被认为是成功放射疗法的主要障碍。因此,迫切需要开发放射增敏剂以改善癌症患者中放射疗法的治疗结果。我们以前使用针对p53和Nrf2的高通量筛选来鉴定新型放射增敏剂的努力揭示了一种有前途的N-
苯基嘧啶-2-胺(
PPA)
铅化合物。在本研究中,研究了该先导化合物的17种衍
生物,发现4-(4-
氟苯基)-N-(4-
硝基苯基)-6-
苯基嘧啶-2-胺(
PPA5),4-(( 4-(4-
氟苯基)
嘧啶-2-基)
氨基)-3-甲氧基-N-甲基-苯甲酰胺(
PPA13),4-((4-(4-
氟苯基)
嘧啶-2-基)
氨基)苯磺酰胺( PP
A14),4-((4-(2-
氯苯基)
嘧啶-2-基)
氨基)苯磺酰胺(
PPA15)和4-((4-(2-
氯苯基)
嘧啶-2-基)
氨基)-N-甲基苯甲酰胺(
PPA17 )将细胞活力抑制了50%以上,并且在细胞周期的G2 / M期停滞的细